PyInvesting

Market research

G49N.F GenSight Biologics S.A

F EUR Healthcare

Latest close

0.0691 —

As of Nov 19, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
17M
P/E ratio
Not available
Analyst target
Not available
Dividend yield
Not available
Beta
0.7

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

GenSight Biologics S.A is currently in a long term uptrend where the price is trading 6.7% above its 200 day moving average.

From a valuation standpoint, the stock is 88.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 154.3.

Based on the above factors, GenSight Biologics S.A gets an overall score of 2/5.